| Home | E-Submission | Sitemap | Contact Us |  
Cancer Research and Treatment > Volume 35(3); 2003 > Article
Cancer Research and Treatment 2003;35(3): 177-180. doi: https://doi.org/10.4143/crt.2003.35.3.177
Treatment of Small Cell Lung Cancer
Atsushi Horiike, Nagahiro Saijo
Division of Internal Medicine, National Cancer CenterHospital, Tokyo, Japan.
  Published online: June 30, 2003.
Among patients with lung cancer, approximately 15% have small cell lung cancer (SCLC), SCLC is usually staged as either limited and extensive. Extensive-stage SCLC is treated primarily with chemotherapy. A recent Japanese randomized trial compared cisplatin and irinotecan (IP) with cisplatin and etoposide (EP). Patients in the IP arm did significantly better than patients in the EP arm. In the IP arm, the response rate was 84%, and the median overall survival period was 12.8 months. Limited- stage SCLC is usually treated with concurrent chemotherapy and accelerated radiation therapy, and approximately 20% of patients are cured. Future research should focus on optimizing chemotherapy regimens and radiation therapy schedules. The role of molecular targeted drugs in the treatment of SCLC must also be evaluated.
Key words: Small cell lung cancer;Chemotherapy;Radiation therapy;Cisplatin;Etoposide;Irinotecan
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI